Climate policies unravel and major technology companies retreat from public climate commitments, creating a sense of defeatism. Despite these headwinds, progress continues. The annual list of Climate Tech Companies to Watch, published by MIT Technology Review, highlights 10 organizations working to reduce emissions and improve public safety in energy storage, nuclear power, and transportation.
Anthropic’s AI Lab Claims First Scientific Discovery
Last week, Anthropic announced a breakthrough from its molecular biology lab. The company stated that its AI agents identified a previously uncatalogued pattern surrounding an enzyme. This pattern, they said, is “reminiscent” of the discovery that led to CRISPR gene-editing technology.
The announcement drew anger from biologists. Some questioned whether simply finding a pattern constitutes a true scientific discovery. One researcher claimed his team had already found the same pattern, raising doubts about whether Anthropic learned the information from their conversations with the Claude AI system.
The incident highlights a challenge in evaluating AI-driven research. What appears novel to a machine may be routine or unimportant to human scientists. High-profile claims from companies can obscure genuine advancements, making it harder to distinguish significant progress from hype.
For researchers, this dynamic adds a layer of friction to adopting new tools. If a lab discovers a pattern that an AI reportedly “found” first, proving the originality of the work becomes complicated. This creates a need for clear documentation and verification standards in collaborative research environments.
Varda Space Industries has signed a deal with United Therapeutics to test whether drugs crystallize differently in microgravity, potentially creating improved versions with new properties. The company says the partnership could mark an important step toward building products in orbit for use back on Earth.
Testing Drug Formulation in Microgravity
The partnership involves sending pharmaceuticals to orbit. The goal is to observe crystal formation in a weightless environment. Different conditions in space can alter how molecules arrange themselves.
Researchers hope to create superior pharmaceutical products. The process could yield drugs with unique properties. These altered properties might improve efficacy or reduce side effects. The venture represents a collaboration between a space logistics company and a medical product firm.
